UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 2, 2005
Xethanol Corporation
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-50154 84-1169517
- --------------------------------------------------------------------------------
(Commission File Number) (IRS Employer Identification No.)
1185 Avenue of the Americas
New York, New York 10036
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(646) 723-4000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Zen Pottery Equipment, Inc.
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Section 5 - Corporate Governance and Management
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers
(d) On June 2, 2005, Louis B. Bernstein was elected to our Board of
Directors, effective immediately.
Mr. Bernstein is currently Assistant General Counsel of Pfizer Inc., where
he has been an attorney for 29 years. In this capacity, Mr. Bernstein has
managed product liability claims and litigation involving prescription
pharmaceuticals, orthopedic implants and other medical devices. Mr. Bernstein
also provides due diligence, financial modeling, market research, acquisition
candidate profiling and strategic partnering advice and assistance to clients in
the life sciences and specialty chemical sectors. In addition, Mr. Bernstein has
related experience in advertising and labeling review, legislative analysis and
consultation regarding new products and investments, food and drug regulatory
matters and commercial transactions.
It has not yet been determined which committees Mr. Bernstein will serve
on.
Mr. Bernstein has not engaged in a related party transaction with us
during the last two years.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.
XETHANOL CORPORATION
Date: June 15, 2005 By: /s/ Christopher d'Arnaud-Taylor
---------------------------------------
Christopher d'Arnaud-Taylor
Chairman and Chief Executive Officer